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REPLY
We read with interest the letter of Schnyder and Turi, and are not
surprised that our study reporting increased complications associ-
ated with arteriotomy closure devices (ACD) has engendered such
a strong and obviously heartfelt response. When a negative study is
generated and subsequently published in the pursuit of academic
honesty and patient well-being (our overriding motivation), one must
regrettably anticipate one-sided and dogmatic reactions from parties
with possible academic, professional or commercial interests at stake.
Unfortunately, Schnyder and Turi have seemingly lost the “forest for
the trees” in their apparent zeal to promote this subspeciality. We shall
attempt to respond point by point to their critique.
The first generation ACDs were approved in the U.S. on the
basis of relatively small randomized trials designed to demonstrate
shorter times to hemostasis compared with manual compression in
patients undergoing diagnostic and interventional procedures.
None of these trials were powered to show differences in compli-
cation rates. Yet notwithstanding differing patient composition,
device sizes and complication definitions, all four studies showed
trends toward increased vascular complications with the ACD,
despite their application in the tightly controlled environment of a
clinical trial (Table 1).
We therefore examined our experience with closure devices in
patients undergoing percutaneous coronary intervention (PCI) at
the Washington Hospital Center, one of the busiest interventional
hospitals in the country, confirming significant increases in hema-
toma formation, large declines in hematocrit, and need for vascular
surgical repair with ACDs (1). Contrary to Schnyder and Turi’s
contention, this was not a “retrospective trial” subject to “bias in
completeness and quality of information recorded in the hospital
chart”; all data were prospectively collected by dedicated research
nurses, all field definitions were prespecified, and all adverse events
adjudicated. These quality measures far outstrip that of the usual
registry based either on retrospective chart review, or physician
recollection or documentation.
Schnyder and Turi are correct though in pointing out potential
hidden physician prejudices; the operators in the present study
were “biased” to tend to use these devices in ideal patients,
explaining why procedure duration was less in patients receiving
ACDs, and in whom less debulking and more stand-alone angio-
plasty were performed, requiring smaller sheaths (2). Nonetheless,
complications were still increased with closure devices despite
these predispositions favoring the ACD group. We further ac-
knowledge that the increased activated clotting time (ACT) levels
at the time of closure device insertion likely favored more bleeding
in the ACD group (1). However, the ability to withdraw sheaths
in the catheter laboratory in the fully anticoagulated patient, rather
than waiting 4 to 6 h for sheath extraction in the in-patient
telemetry unit prior to manual compression, is a purported advan-
tage of ACDs and the standard way these devices are utilized.
Certainly, Schnyder and Turi are not suggesting ACT normaliza-
tion is required before using a closure device, which would obviate
much of the device’s clinical desirability.
Schnyder and Turi criticize the physicians involved in this study
as being “largely novices at vascular closure, having apparently
failed to adopt them in routine use.” The great majority of the
closure procedures were performed by four senior physicians, who
collectively have performed 25,000 PCI procedures and many
more diagnostic angiograms. They note, however, that only 150
ACD procedures were being done per year in the study by these
physicians; this is true if only “interventional” procedures are
considered—the same four operators performed approximately
two- to threefold this many closure procedures annually on
diagnostic patients. Furthermore, the physicians involved have
been participating investigators in most of the premarket approval
ACD clinical trials. Thus, while we do not profess to possess the
expertise of Schnyder and Turi, the volume and experience with
ACDs represented in the present report certainly would more than
match the real-world qualifications of most centers experienced in
both traditional and novel methods of arteriotomy closure.
Schnyder and Turi also repeatedly note that not all patients in
our study had a preclosure femoral angiogram. Though we did not
collect this data, we believe 90% of patients did undergo such
examination, a frequency that is likely greater than at most
hospitals using ACDs in the “real world.” Indeed, one reason why
more patients did not receive closure devices in our study was the
low threshold in place to exclude patients upon the identification
of disease or calcification at the access site, an excessively low
puncture, or small vessel diameter. Furthermore, femoral angiog-
raphy was not performed in the manual compression group, and
cases unsuitable for closure devices on the basis of the angiogram
were also included in the manual compression group, both factors
that would favor the ACD group. Finally, to our knowledge, no
prior study (whether real-world or controlled trial) has ever
reported the actual frequency with which the recommended
femoral angiogram was in fact performed.
Schnyder and Turi state that “multiple studies have reported far
larger experiences” (2–4), taking issue with our statement that
large postapproval studies with these devices were lacking. At the
time of submission for publication, our analysis of 6,408 interven-
tional procedures was indeed the only large experience with 500
ACDs investigating femoral access complications after PCI; the
three referenced single-center studies were published afterward.
Regardless, these subsequent experiences largely support our find-
ings.
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In the observational study by Cura et al. (2) comparing the
outcomes of manual compression with ACDs in 2,918 patients,
the suture-based device was associated with increased rates of
vascular access site infections (0.5% vs. 0%) and need for surgery
(1.0% vs. 0.4%) compared with manual compression, while both
suture and collagen plug ACDs resulted in increased rates of
retroperitoneal hematoma (despite the institutional requirement
for femoral angiograms before device usage), and a trend toward
doubling of the rate of access site–related blood transfusions. In the
3,699-patient quality control study of Carey et al. (3), compared
with manual compression the collagen plug devices resulted in
greater rates of major vascular complications and hospital readmis-
sion, whereas both collagen plug and suture-based ACDs in-
creased rates of infection.
Finally, Schnyder and Turi reference the 930-patient study of
Balzer et al. (4), in which a suture-based closure device was used in
all patients, with no control group. Technical success was achieved
in only 92% of patients, and a relatively high rate of patients (7.0%)
had an access site complication, including a 4.1% incidence of large
hematomas (6 cm). They described a learning curve for technical
success extending beyond 350 treated patients (although it is
unclear how many operators performed these procedures, and
whether or not the rate of complications decreased with experience
in concert with rising device hemostasis rates). In any event, one
can question the wisdom of using a costly device to replace
something as simple and effective as manual compression if 350
procedures are required for mastery!
Thus, the bulk of data (not rhetoric) generated to date supports
the contention that vascular closure devices may increase compli-
cations in patients undergoing percutaneous interventional proce-
dures. Certainly, no studies exist to suggest that complications are
decreased with these devices. Given the fact that ACDs are used
primarily for patient comfort (or more rapid ambulation, although
the potential economic gains from early discharge in this regard
have not been realized owing to insurance requirements of an
overnight stay after PCI for full reimbursement), and add signif-
icant capital cost to an already extended healthcare budget, we
question whether closure devices should be used in most post-PCI
patients prior to demonstration of their safety in an adequately
powered postmarket registry study. In this regard we are concerned
that Schnyder and Turi, based on no firm academic footing, “use
these devices after percutaneous intervention in nearly 100% of . . .
cases” and feel that further recommendations “should await the
results of prospective, randomized studies.” While the call for
randomized controlled studies can never be criticized, Schnyder
and Turi are no doubt aware that such a trial, designed to show
noninferiority in vascular complications between manual compres-
sion and ACDs with a relative delta of 20%, would require
enrollment of 8,000 patients, and will thus never be performed.
Moreover, though this is not the first time the researchers have
been critical of other investigators’ work in this field (5), to our
knowledge they have not reported their own patient outcomes with
and without closure devices, which would be welcome.
In the final analysis, in the interest of our patients we must not
succumb to the hazards of anecdotal medicine or the lure of the
latest and greatest drug or device. For this reason the results of all
credible large-scale postmarket studies, whether prospective, ret-
rospective, case-controlled or registry-based, must be seriously
considered by the thoughtful operator in light of the physician’s
Hippokratic oath—primum non nocere—first, do no harm. A few
additional hours of patient comfort or nursing convenience does
not justify even a 1% increase in the rate of septic endarteritis, large
hematoma, or the need for blood transfusion or vascular surgical
repair. Even the Food and Drug Administration, the uncondi-
tional guardian of the public health, realizes the limitations
inherent in the best intentioned premarket studies, and thus the
need for vigorous postmarket surveillance (6). We remain hopeful
that with increasing operator experience and technical device
evolution the promise of ACDs will be realized, and we implore
the collaboration of our physician–scientist, regulatory and indus-
try partners to obtain confirmatory evidence.
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Table 1. Instruction for Use of Package Inserts, Data on File, Food and Drug Administration
Device
Description
Sheath Sizes
Tested
PCI
(%)
Device
Complications
(%)
Control
Complications
(%)
p
Value
Vasoseal (n  568) Collagen plug  8F 71 14.3 10.8 NS
Angio-Seal (n  397) Collagen plug  8F 23 5.6 4.5 NS
Prostar (n  501) Suture based 8F–11F — 6.0 4.0 NS
Duett (n  629) Thrombin/collagen 5F–9F 67 7.1 3.8 NS
Pooled (n  2,095) — — — 8.5 5.9 0.02
PCI  percutaneous coronary intervention.
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Dobutamine Stress Testing Revisited
I read with great interest the recently published study by Calnon et
al. (1), which analyzed the clinical outcome of patients who under-
went dobutamine stress single-photon emission computed tomogra-
phy (SPECT) Tc-99m-sestamibi imaging. Two aspects of this study
are rather intriguing, and deserve further examination.
First, the annual “hard” cardiac event rate in patients with
normal dobutamine SPECT studies was 2.3%. This is more than
twofold higher than previously published event rates after a normal
exercise stress perfusion study (1%). It is also substantially higher
than previously reported in other patients with normal dobutamine
SPECT. Previous studies, including a large series by Geleijnse et
al. (2), reported an annual event rate of 0.8% for hard events, and
2.5% for all cardiac events in patients with normal dobutamine
Tc-99m-sestamibi SPECT studies. As stated by the investigators
(1), some “probably normal” studies were grouped into the “normal
study” category, and neither attenuation correction nor gated
analyses were used in most studies. It is possible that these factors
may have affected observed event rates.
Second, the multivariate analysis identified the electrocardio-
gram (ECG) response and SPECT perfusion results as independent
predictors of cardiac events after accounting for clinical variables. As
a group, patients with abnormal ST-segment changes and normal
myocardial perfusion had a similar intermediate rate of events as did
those with perfusion defects but without abnormal ST-segment
changes on their ECG. This is a very interesting finding, and has the
potential for changing our common clinical practice.
It may be helpful to separate the two groups with intermediate
event rates and report the outcome separately for each group.
Commonly, patients with SPECT scans revealing no perfusion
abnormalities or ancillary findings suggestive of coronary artery
disease, but with ischemic ST-segment changes during dobut-
amine stress, are often classified as “normal.” Thus, it will be
particularly useful to know whether the outcome in this group
differed significantly from a subgroup of dobutamine stress patients
with normal ECG and normal perfusion. If, indeed, patients with
abnormal ST-segment changes but normal perfusion during do-
butamine stress testing have an intermediate event rate, it would be
interesting to know whether any significant clinical variables might
explain a relatively high event rate in this subset.
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REPLY
Our observation of a relatively high cardiac event rate in patients
with normal dobutamine Tc-99m-sestamibi single-photon emis-
sion computed tomography (SPECT) studies must be considered
in the context of the high intrinsic risk of the population referred
for dobutamine perfusion imaging at our institution (1). We
reserve dobutamine for patients who are unable to perform adequate
exercise and have contraindications to adenosine or dipyridamole
stress. Geleijnse et al. (2) used dobutamine more liberally (e.g.,
included patients without contraindications to vasodilator stress),
which might have contributed to the lower cardiac event rates
observed in patients with normal dobutamine Tc-99m-sestamibi
SPECT studies at their institution. Geleijnse et al. (2) assigned
patients with “equivocal defects” to the “normal scan” group, and
studies were interpreted without the use of electrocardiogram (ECG)-
gating or attenuation correction. It is therefore unlikely that these
technical factors were responsible for the higher cardiac event rates in
patients with normal dobutamine Tc-99m-sestamibi SPECT scans in
our study. We believe that the higher cardiac event rates reflect the
high intrinsic risk of the population referred for dobutamine perfusion
imaging at our institution. This conclusion is supported by the
significantly higher cardiac event rate in patients with abnormal
dobutamine Tc-99m-sestamibi SPECT studies (1) than in patients
with abnormal exercise Tc-99m-sestamibi SPECT studies (3).
We agree that the subgroup of patients (n  23) with
dobutamine-induced ST- depression and normal SPECT results is
of particular clinical interest. Absence of a perfusion defect could
have resulted from “balanced” myocardial ischemia due to diffuse
coronary disease without a normally perfused myocardial region,
though this phenomenon is rare and unlikely to have occurred in
all 23 patients. Only three total cardiac events were observed in this
subgroup (one cardiac death and two nonfatal myocardial infarc-
tions [MIs]), but the annual cardiac event rates were relatively high
owing to the small sample size (cardiac death and nonfatal MI
rates of 2.6% and 5.2%, respectively). These findings should be
confirmed in a larger group of patients before specific recommen-
dations are made regarding management of patients with
dobutamine-induced ST depression and normal SPECT images.
The larger subgroup of patients (n  129) with normal ECG
responses but abnormal SPECT images had a high rate of cardiac
events (10 cardiac deaths [4.5%/year] and 8 nonfatal MIs [3.6%/
year]). This subgroup of patients should be considered at high risk
for cardiac events and should be managed accordingly.
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